These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25332275)

  • 1. Challenges in treating liver fibrosis.
    Poo JL; Muñoz LE
    Ann Hepatol; 2014; 13(6):845-6. PubMed ID: 25332275
    [No Abstract]   [Full Text] [Related]  

  • 2. A pilot study in patients with established advanced liver fibrosis using pirfenidone.
    Armendáriz-Borunda J; Islas-Carbajal MC; Meza-García E; Rincón AR; Lucano S; Sandoval AS; Salazar A; Berumen J; Alvarez A; Covarrubias A; Aréchiga G; García L
    Gut; 2006 Nov; 55(11):1663-5. PubMed ID: 17047115
    [No Abstract]   [Full Text] [Related]  

  • 3. Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.
    Grizzi F
    Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):961-2. PubMed ID: 19650793
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical decisions in hepatology: the pirfenidone case analysis.
    Chavez-Tapia NC; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(2):163-5. PubMed ID: 24552857
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.
    Richeldi L
    Clin Respir J; 2012 Jul; 6(3):129-30. PubMed ID: 22697263
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges.
    Nat Rev Drug Discov; 2010 Jul; 9(7):506. PubMed ID: 20592735
    [No Abstract]   [Full Text] [Related]  

  • 7. The questionable efficacy of pirfenidone in IPF.
    Mathai SC; Polito AJ
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228. PubMed ID: 16249323
    [No Abstract]   [Full Text] [Related]  

  • 8. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
    Levitt J; Gould MK
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228-9; author reply 1229. PubMed ID: 16249322
    [No Abstract]   [Full Text] [Related]  

  • 9. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 10. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
    Kingwell K
    Nat Rev Drug Discov; 2014 Jul; 13(7):483-4. PubMed ID: 24981347
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimal treatment for idiopathic pulmonary fibrosis.
    Maher TM; Wells AU
    Thorax; 2008 Dec; 63(12):1120-1; author reply 1121. PubMed ID: 19020278
    [No Abstract]   [Full Text] [Related]  

  • 12. [Idiopathic pulmonary fibrosis: treatment with pirfenidone].
    Cano-Jiménez E
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():16-8. PubMed ID: 23630972
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological therapy does not contribute to survival in idiopathic pulmonary fibrosis.
    Ishii H; Kushima H; Komiya K; Mizunoe S; Kadota J
    Respiration; 2013; 86(1):86-7. PubMed ID: 23594834
    [No Abstract]   [Full Text] [Related]  

  • 14. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.
    Armendáriz-Borunda J; Rincón AR; Muñoz-Valle JF; Bueno-Topete M; Oregón-Romero E; Islas-Carbajal MC; Medina-Preciado D; González-García I; Bautista CA; García-Rocha S; Godoy J; Vázquez-Del Mercado M; Troyo-SanRoman R; Arellano-Olivera I; Lucano S; Alvarez-Rodríguez A; Salazar A
    J Investig Med; 2008 Oct; 56(7):944-53. PubMed ID: 18797412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patient treated with pirfenidone].
    Valenzuela C
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():19-20. PubMed ID: 23630973
    [No Abstract]   [Full Text] [Related]  

  • 17. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel treatments for idiopathic pulmonary fibrosis.
    Spagnolo P
    Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antifibrotic treatment].
    von der Beck D; Löh B; Drakopanagiotakis F; Markart P; Günther A
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2523-5. PubMed ID: 25423462
    [No Abstract]   [Full Text] [Related]  

  • 20. Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation.
    Antoniu SA
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1443-7. PubMed ID: 16255682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.